137 related articles for article (PubMed ID: 25661551)
1. The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control.
Sankaralingam S; Kim RB; Padwal RS
Can J Cardiol; 2015 Feb; 31(2):167-76. PubMed ID: 25661551
[TBL] [Abstract][Full Text] [Related]
2. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
Czernichow S; Knol MJ; Fezeu L; Grobbee DE
Eur J Prev Cardiol; 2012 Jun; 19(3):484-9. PubMed ID: 21464100
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment of obesity in cardiovascular disease.
Charakida M; Finer N
Am J Cardiovasc Drugs; 2012 Apr; 12(2):93-104. PubMed ID: 22292446
[TBL] [Abstract][Full Text] [Related]
4. Obesity and cardiovascular risk: the new public health problem of worldwide proportions.
Scaglione R; Argano C; Di Chiara T; Licata G
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):203-12. PubMed ID: 15151469
[TBL] [Abstract][Full Text] [Related]
5. Dosing of antibacterial agents in obese adults: does one size fit all?
Payne KD; Hall RG
Expert Rev Anti Infect Ther; 2014 Jul; 12(7):829-54. PubMed ID: 24809811
[TBL] [Abstract][Full Text] [Related]
6. Perioperative pharmacology in morbid obesity.
Lemmens HJ
Curr Opin Anaesthesiol; 2010 Aug; 23(4):485-91. PubMed ID: 20531173
[TBL] [Abstract][Full Text] [Related]
7. Obesity: new perspectives and pharmacotherapies.
Palamara KL; Mogul HR; Peterson SJ; Frishman WH
Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
[TBL] [Abstract][Full Text] [Related]
8. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.
Pai MP
Pharmacotherapy; 2012 Sep; 32(9):856-68. PubMed ID: 22711238
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of drugs in obesity. An update.
Cheymol G
Clin Pharmacokinet; 1993 Aug; 25(2):103-14. PubMed ID: 8403734
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.
Natale S; Bradley J; Nguyen WH; Tran T; Ny P; La K; Vivian E; Le J
Pharmacotherapy; 2017 Mar; 37(3):361-378. PubMed ID: 28079262
[TBL] [Abstract][Full Text] [Related]
11. Why do we need drugs to treat the patient with obesity?
Bray GA
Obesity (Silver Spring); 2013 May; 21(5):893-9. PubMed ID: 23520198
[TBL] [Abstract][Full Text] [Related]
12. New medications for treatment of obesity: metabolic and cardiovascular effects.
Pucci A; Finer N
Can J Cardiol; 2015 Feb; 31(2):142-52. PubMed ID: 25661549
[TBL] [Abstract][Full Text] [Related]
13. What is the best size descriptor to use for pharmacokinetic studies in the obese?
Green B; Duffull SB
Br J Clin Pharmacol; 2004 Aug; 58(2):119-33. PubMed ID: 15255794
[TBL] [Abstract][Full Text] [Related]
14. Effects of obesity on pharmacokinetics implications for drug therapy.
Cheymol G
Clin Pharmacokinet; 2000 Sep; 39(3):215-31. PubMed ID: 11020136
[TBL] [Abstract][Full Text] [Related]
15. [Xenical--a modern perspective drug for the treatment of obesity (review)].
Mkrtumian AM; Biriukova EV
Ter Arkh; 2007; 79(10):35-9. PubMed ID: 18154143
[No Abstract] [Full Text] [Related]
16. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.
Czernichow S; Lee CM; Barzi F; Greenfield JR; Baur LA; Chalmers J; Woodward M; Huxley RR
Obes Rev; 2010 Feb; 11(2):150-8. PubMed ID: 19573052
[TBL] [Abstract][Full Text] [Related]
17. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
18. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
19. Drug treatment of obesity in the cardiovascular patient.
Charakida M; Tousoulis D; Finer N
Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
